**Behavioral/Systems/Cognitive**

**Glucocorticoid Effects on Memory Consolidation Depend on Functional Interactions between the Medial Prefrontal Cortex and Basolateral Amygdala**

Benno Roozendaal,1 Jayme R. McReynolds,2 Eddy A. Van der Zee,3 Sangkwan Lee,4 James L. McGaugh,4 and Christa K. McIntyre2

1Department of Neuroscience, Section Anatomy, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, The Netherlands, 2School of Behavioral and Brain Sciences, University of Texas, Dallas, Dallas, Texas 75083, 3Department of Molecular Neurobiology, University of Groningen, 9750 AA Haren, The Netherlands, and 4Center for the Neurobiology of Learning and Memory, Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697-3800

Considerable evidence indicates that the basolateral complex of the amygdala (BLA) interacts with efferent brain regions in mediating glucocorticoid effects on memory consolidation. Here, we investigated whether glucocorticoid influences on the consolidation of memory for emotionally arousing training depend on functional interactions between the BLA and the medial prefrontal cortex (mPFC), a brain region involved in higher-order cognitive and affective processing. The glucocorticoid receptor (GR) agonist 11β,17β-dihydroxy-6,21-dimethyl-17α-pregna-4,6,20-trien-3-one (RU 28362) administered unilaterally into the left mPFC of male Sprague Dawley rats immediately after inhibitory avoidance training enhanced 48 h retention performance. An ipsilateral, but not contralateral, lesion of the BLA blocked the memory enhancement. In a second experiment, RU 28362 infused into the mPFC after inhibitory avoidance training increased BLA levels of phosphorylated extracellular signal-regulated kinase 1/2 (pErk1/2). Blockade of this pErk1/2 activity in the BLA immediately after inhibitory avoidance training enhanced 48 h retention performance. An ipsilateral, but not contralateral, lesion of the BLA blocked the memory enhancement. In a third experiment, RU 28362 infused into the mPFC after inhibitory avoidance training increased BLA levels of phosphorylated extracellular signal-regulated kinase 1/2 (pErk1/2). Blockade of this pErk1/2 activity in the BLA with the mitogen-activated protein kinase kinase inhibitor PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] prevented the memory enhancement, suggesting that GR agonist administration into the mPFC enhances memory consolidation via modulation of BLA activity. Conversely, GR agonist infusions administered into the BLA posttraining increased pErk1/2 levels in the mPFC in regulating memory consolidation. Moreover, as assessed with a two-phase inhibitory avoidance procedure designed to separate modulatory influences on memory of context and footshock, posttraining GR agonist infusions into either the BLA or mPFC enhanced memory of the contextual as well as aversive information acquired during inhibitory avoidance training. These findings indicate that glucocorticoid effects on memory consolidation depend on bidirectional interactions between the BLA and mPFC.

**Introduction**

It is well established that glucocorticoid hormones, released from the adrenal cortex in response to stressful stimuli, strengthen the consolidation of long-term memories of emotionally arousing experiences (de Kloet et al., 1999; Roozendaal, 2000; McGaugh and Roozendaal, 2002; Sandi and Pinelo-Nava, 2007). The basolateral complex of the amygdala (BLA), which has a moderate density of glucocorticoid receptors (GRs), is crucially involved in mediating glucocorticoid effects on memory consolidation. A GR agonist infused into the BLA after training enhances memory consolidation (Roozendaal and McGaugh, 1997b; Roozendaal et al., 2002), whereas lesions or temporary inactivation of the BLA block the memory-enhancing effect of systemically administered glucocorticoids (Roozendaal and McGaugh, 1996; Roozendaal et al., 1996; Quirarte et al., 1997). Glucocorticoid-induced amygdala activation is known to enhance memories of emotionally arousing training experiences via efferent projections that activate many other brain regions, including the hippocampus, dorsal striatum, and neocortical regions (Roozendaal and McGaugh, 1997a; Dolcos et al., 2004; McIntyre et al., 2005; Huff et al., 2006; Tsoory et al., 2008).

A growing body of evidence indicates that BLA neuronal activity is closely regulated by the medial prefrontal cortex (mPFC), a brain region involved in higher-order cognitive and affective processing as well as executive function (Davidson, 2002; Quirk and Gehlert, 2003). The evidence suggests that there are reciprocal connections between the mPFC and BLA (Pérez-Jaray and Vives, 1991; Rosenkranz and Grace, 2002; Likhtik et al., 2005) that regulate affect and memory (Garcia et al., 1999; Milad and Quirk, 2002; Laviolette et al., 2005; Laviolette and Grace, 2006). Maintenance of mPFC activity is known to constrain BLA activ-
ity, whereas stress and glucocorticoids alter mPFC functioning, thereby increasing BLA responses to emotionally arousing stimuli (Lyons et al., 2000; Amat et al., 2005). Like the BLA, mPFC functioning is known to influence the consolidation of memory of emotionally arousing training (Runyan and Dash, 2004; Akirav and Maroun, 2006; Izquierdo et al., 2007). However, previous studies have not investigated whether the mPFC and BLA interact in regulating memory consolidation. Moreover, previous experiments have not investigated whether the mPFC is a locus of glucocorticoid action in regulating memory consolidation.

To address these issues, a first experiment examined whether the specific GR agonist 11β,17β-dihydroxy-6,21-dimethyl-17α-pregn-4-6-trien-20yn-3-one (RU 28362) administered into the mPFC immediately after emotionally arousing inhibitory avoidance training enhances memory consolidation and whether such memory enhancement requires an intact BLA. The next experiment investigated whether posttraining GR agonist infusions into the mPFC increase BLA activity and whether such BLA activation is required for mediating the memory-modulatory effects of intra-mPFC GR agonist administration. BLA activity was assessed by determining phosphorylation levels of extracellular signal-regulated kinase 1/2 (pErk1/2), a signaling cascade implicated in memory consolidation (Duvarcı et al., 2005; Merino and Maren, 2006). Because of the strong reciprocal interaction between these brain regions, the experiments also examined whether the well known memory consolidation enhancement induced by GR agonist infusions into the BLA depends on concurrent changes in pErk1/2 activity levels within the mPFC. A final experiment investigated whether RU 28362 infused into either the mPFC or BLA induces comparable effects on memory of the contextual and aversive information acquired during inhibitory avoidance training.

Materials and Methods

Subjects. Adult male Sprague Dawley rats (270–320 g at time of surgery) from Charles River Breeding Laboratories were housed individually in a temperature-controlled (22°C) vivarium room and maintained on a standard 12 h light/dark cycle (7:00 A.M. to 7:00 P.M. lights on). Food and water were available ad libitum. Training and testing were performed during the light phase of the cycle between 10:00 A.M. and 3:00 P.M., at the rat nadir of the circadian cycle for corticosterone (Duvarcı et al., 2005; Merino and Maren, 2006). Because of the strong reciprocal interaction between these brain regions, the experiments also examined whether the well known memory consolidation enhancement induced by GR agonist infusions into the BLA depends on concurrent changes in pErk1/2 activity levels within the mPFC. A final experiment investigated whether RU 28362 infused into either the mPFC or BLA induces comparable effects on memory of the contextual and aversive information acquired during inhibitory avoidance training.

Inhibitory avoidance apparatus and procedures. For all experiments, the rats were trained in an inhibitory avoidance apparatus consisting of a trough-shaped alley (91 cm long, 15 cm deep, 20 cm wide at the top, and 6.4 cm wide at the bottom) divided into two compartments, separated by a sliding door that opened by retracting into the floor (McGaugh et al., 1988). The starting compartment (31 cm) was made of opaque white plastic and well lit; the shock compartment (60 cm) was made of dark, electroifiable metal plates and was not illuminated. Training and testing were conducted in a sound- and light-attenuated room.

For one-trial inhibitory avoidance training, the rats were placed in the starting compartment of the apparatus, facing away from the door, and were allowed to enter the dark (shock) compartment. After the rat stepped completely into the dark compartment, the sliding door was closed and a single inescapable footshock (0.35 mA; 1 s) was delivered. The rats were removed from the shock compartment 15 s later and, after drug treatment, returned to their home cages. For the modified, two-phase inhibitory avoidance procedure (Malin and McGaugh, 2006), on the first day (context training), the rat was placed into the starting compartment and allowed to freely explore the inhibitory avoidance apparatus for 3 min. On day 2 (shock training), each rat was placed into the dark compartment, facing away from the starting compartment, with the retractable door closed. The rat then received an inescapable footshock and immediately afterward was removed from the training apparatus. Rats of the mPFC experiment received a footshock intensity of 0.67 mA for 1 s. As the vehicle contained 1% ethanol, which is slightly impairing when infused into the BLA, the BLA-cannulated rats received a somewhat higher footshock intensity of 1.0 mA for 2 s to ensure memory in all experimental groups. For both one-trial and two-phase inhibitory avoidance, retention was tested 48 h after training by placing the rat into the starting compartment of the inhibitory avoidance apparatus and measuring the latency to enter the former shock compartment with all four paws (maximum latency of 600 s). Longer latencies were interpreted as indicating better retention. Shock was not administered on the retention test trial.

Drug treatment. The specific GR agonist RU 28362 (Roussel Uclaf) was dissolved in 0.2 l of phosphate buffer) was infused over a 25 s injection volume was infused into the mPFC (3 or 10 ng in 0.5 μl) or BLA (1 or 3 ng in 0.2 μl). Receptor binding studies have shown that this compound has selective and high affinity for GRs (Teutsh et al., 1981). RU 28362 was first dissolved in 100% ethanol and subsequently diluted in 0.9% saline to reach a final ethanol concentration of 1%. Bilateral infusions of RU 28362 or an equivalent volume of vehicle (1% ethanol in saline) into these brain regions were given immediately after inhibitory avoidance training by using a 30 gauge injection needle connected to a 10 μl Hamilton microsyringe with polyethylene (PE-20) tubing. The use of posttraining drug administration provides direct support for the view that the treatment affects memory consolidation processes and that the retention performance is, thus, not confounded by possible effects on attentional, motivational, or sensory-perceptual mechanisms at the time of training or test (McGaugh, 1966). For mPFC infusions, the injection needle protruded 1.5 mm beyond the tip of the cannula and a 0.5 μl injection volume was infused over a period of 35 s by an automated syringe pump (Sage Instruments). For BLA infusions, the injection needle protruded 2.0 mm beyond the cannula tip and a 0.2 μl injection volume was infused during 25 s. The injection needles were retained within the cannulae for an additional 20 s after drug infusion to maximize diffusion and to prevent backflow of drug into the cannulae. For some experiments, the GR agonist was administered unilaterally into either the mPFC or BLA together with the specific mitogen-activated protein kinase kinase (MEK)
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059) into the other brain region immediately after inhibitory avoidance training. PD98059 acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by MEK kinase. PD98059 avoids training. PD98059 acts by binding to the inactivated form of ERK1/2 as primary antibody overnight (1:1000; Cell Signaling). The sections were then incubated for 2 h with biotinylated goat anti-rabbit IgG (1:400; Jackson ImmunoResearch Laboratories) and visualized using ABC kits (Vector Laboratories) according to the manufacturer’s instructions.

**Statistics.** Inhibitory avoidance training and retention latencies were analyzed with one- or two-way ANOVAs. The source of the detected significances was determined by Fisher’s post hoc tests. To determine whether learning had occurred, paired t tests were used to compare the training and retention latencies of the vehicle groups. Western blot data were expressed as ratio of normalized pErk1/2 across hemispheres (ipsilateral to infusion/contralateral to infusion), and ratios were compared across groups with one-way ANOVAs. Data are expressed as mean ± SEM. Values of p < 0.05 were considered statistically significant. The number of rats per group is indicated in the figure legends.

**Results.**

**Ipsilateral, but not contralateral, lesions of the BLA block inhibitory avoidance retention enhancement induced by postraining intra-mPFC infusions of a GR agonist.**

This experiment examined whether immediate postraining infusions of a GR agonist administered into the mPFC would enhance 48 h retention performance of inhibitory avoidance training and whether this retention enhancement depends on an intact BLA. To address this issue, unilateral infusions of the GR agonist RU 28362 (3 or 10 ng) or vehicle were administered into the left mPFC immediately after inhibitory avoidance training to rats with an NMDA-induced lesion of either the ipsilateral or contralateral BLA.

Average step-through latencies for all groups during training (i.e., before footshock or drug treatment) were 12.6 ± 0.6 s (mean ± SEM). In rats with lesions or sham lesions of the left BLA, a two-way ANOVA for entrance latencies during training showed no BLA lesion effect (F(1,62) = 0.15; p = 0.70). Also, rats in different postraining drug groups did not differ in their latencies during training (F(2,62) = 0.88; p = 0.42). In rats with lesions or sham lesions of the right BLA, there were also no significant lesion (F(1,59) = 0.04; p = 0.84) or drug group effects (F(2,59) = 0.77; p = 0.49) (data not shown).

Lesions of the ipsilateral BLA blocked the memory-enhancing effect of postraining intra-mPFC infusions of RU 28362. Figure 1A shows 48 h retention latencies of rats with sham- or NMDA-induced lesions of the left BLA given postraining infusions of RU 28362 into the left mPFC. Retention latencies of sham-lesioned rats treated with vehicle were significantly longer than their entrance latencies during training (paired t test, p < 0.001), indicating memory for the training experience. Two-way ANOVA for retention latencies showed no significant RU 28362 effect (F(2,62) = 1.78; p = 0.17) but did show a significant lesion (F(1,62) = 14.01; p < 0.0005) and interaction effect between both factors (F(2,62) = 3.27; p < 0.05). Additional analysis with Fisher’s post hoc tests showed that, in sham-lesioned rats, postraining infusions of the higher dose of RU 28362 (10 ng) enhanced retention (p < 0.05, compared with vehicle), whereas retention latencies of animals given the lower dose (3 ng) approached, but failed to reach, significance (p = 0.06). A lesion of the BLA made ipsilaterally to the mPFC infusion side alone did not affect retention (p = 0.71), but blocked the retention-enhancing effect of RU 28362 infused into the mPFC. Retention latencies of BLA-lesioned rats given either dose of RU 28362 were significantly shorter than those of corresponding sham-lesioned rats (both, p < 0.05).
In contrast, a lesion of the contralateral BLA did not block the retention enhancement induced by immediate posttraining intra-mPFC administration of RU 28362 (Fig. 1B). Two-way ANOVA for 48 h retention latencies showed a significant RU 28362 effect ($F_{(2,59)} = 7.85; p < 0.001$), but no lesion effect ($F_{(1,59)} = 0.10; p = 0.75$) or interaction effect between both factors ($F_{(2,59)} = 0.01; p = 0.99$). Administration of the higher dose of RU 28362 (10 ng) into the mPFC enhanced retention in both sham-lesioned ($p < 0.05$) and BLA-lesioned rats ($p < 0.01$).

Cannula placement in the mPFC is shown in Figure 1C. All injection needle tips of rats included in the analysis were localized in the prelimbic region of the mPFC. A total of 10 rats with improper cannula placement or extensive tissue damage at the injection needle tip site was excluded from additional analysis. Histological examination of the lesioned BLA indicated that the lesioned area was characterized by pyknosis and loss of neurons, accompanied by extensive gliosis. In several animals, the BLA lesion was not complete, leaving most of the anterior part intact, but typically 50% or more of the nucleus was damaged. Thirteen rats with improper lesions of either the ipsilateral or contralateral BLA were excluded from analysis. In some animals, whose data were included in the analyses, minor damage was seen in the cortex adjacent to the BLA but the central nucleus of the amygdala was intact in all animals. Figure 1D shows the extent of minimum and maximum BLA lesions of rats included in the experiment.

**GR agonist infusions into the mPFC after inhibitory avoidance training increase pErk1/2 levels in the BLA**

As indicated above, manipulation of mPFC activity can alter BLA neuronal activity (Rosenkranz and Grace, 2002; Liktitik et al., 2005). And, as the BLA is critically involved in modulating memory consolidation, it seems possible that manipulation of GR activity in the mPFC after inhibitory avoidance training enhanced memory consolidation via influencing BLA activity. To examine whether posttraining infusions of RU 28362 into the mPFC modulate BLA activity, pErk1/2 levels in the BLA were assessed in rats given vehicle or RU 28362 (3 or 10 ng in 0.5 μl) into the left mPFC immediately after inhibitory avoidance training. As the findings of the previous experiment indicate that the GR agonist infused into the mPFC was only blocked by an ipsilateral, and not contralateral BLA lesion, we compared pErk1/2 levels, normalized to total MAP kinase levels (Patterson et al., 2001; Sharma et al., 2003), in the BLA of the stimulated side with that of the nonstimulated control side. Figure 2A shows the ratio of pErk1/2 expression in the BLA across the two hemispheres. One-way ANOVA revealed a significant difference across groups ($F_{(2,24)} = 5.02; p < 0.05$). For rats given infusions of RU 28362 into the mPFC after inhibitory avoidance training, the ratio of pErk1/2 protein levels in the BLA between the ipsilateral and contralateral side was significantly greater than that seen in rats receiving vehicle infusions (3 ng, $p < 0.05$; 10 ng, $p < 0.01$). Importantly, pErk1/2 levels in the BLA did not increase after infusions of RU 28362 into the mPFC of control rats that were not trained on the inhibitory avoidance task ($F_{(2,14)} = 1.59; p = 0.24$). Figure 2B shows a representative example of an immunoblot illustrating pErk1/2 and total MAP kinase levels in the ipsilateral and contralateral BLA of the different experimental groups.

Some animals were processed for immunocytochemistry to qualitatively confirm the Western blot data and to determine the location of increased pErk1/2 activity within the BLA. As is shown in Figure 2C, posttraining infusions of RU 28362 (10 ng) into the mPFC increased the density of pErk1/2-positive neurons scattered throughout the BLA. The BLA of the vehicle-infused control group was almost devoid of pErk1/2-positive cells. Furthermore, and even more pronounced, more pErk1/2-immunoreactive cells were present in the central part of the lateral division of the central nucleus. The pErk1/2-positive cells represent the multipolar principal cells of the amygdalar subnuclei. Increased density of pErk1/2 cells was also found in the medial amygdalar nucleus, whereas the other subnuclei of the amygdala revealed pErk1/2-stained cells only occasionally. The
between both factors (two hemispheres of vehicle-treated rats. Measured in the contralateral BLA is significantly greater in rats administered RU 28362 than the ratio of the comparison across the two hemispheres of vehicle-treated rats. *p < 0.05; **p < 0.01 (n = 6–11 per group). No significant differences were observed across hemispheres in rats that were not trained on the inhibitory avoidance task (n = 5–6 per group). B, Density of pErk1/2 bands was normalized to density of total MAP kinase bands on the same blot. Left band is ipsilateral (i) to mPFC infusion, and right is contralateral (c). C, Immunohistochemical demonstration of location of pErk1/2 within the amygdala. Positive cells were present in the BLA as well as in the central part of the lateral division of the central nucleus (CEA). A MEK inhibitor infused into the BLA blocks retention enhancement induced by postraining infusion of a GR agonist into the mPFC

If the increased pErk1/2 expression in the BLA plays a role in mediating the memory-enhancing effect of RU 28362 infused into the mPFC, then a blockade of pErk1/2 activity in the BLA should prevent the retention enhancement induced by immediate postraining intra-mPFC administration of the GR agonist. To investigate this issue, rats were given unilateral infusions of the specific MEK inhibitor PD98059 (20 ng in 0.2 μl) or vehicle into the left BLA together with the GR agonist RU 28362 (3 or 10 ng) or vehicle into the ipsilateral mPFC immediately after inhibitory avoidance training. Two-way ANOVA for entrance latencies on the training trial, before footshock and drug treatment, did not show significant differences between groups (p > 0.05 for all comparisons) (data not shown). As shown in Figure 3A, two-way ANOVA for retention latencies revealed a significant RU 28362 effect (F(2,62) = 3.53; p < 0.05), a significant PD98059 effect (F(1,62) = 7.62; p < 0.01), as well as a significant interaction between both factors (F(2,62) = 5.07; p < 0.01). Posttraining infusions of the higher dose of RU 28362 (10 ng) into the mPFC enhanced retention of rats given vehicle into the BLA, compared with the retention of corresponding vehicle-treated rats (p < 0.01). Infusion of a low dose of the MEK inhibitor into the ipsilateral BLA did not impair retention latencies when administered alone (p = 0.34) but blocked the retention-enhancing effect of RU 28362 administered into the mPFC. Retention latencies of RU 28362-treated rats given PD98059 into the ipsilateral and contralateral mPFC. Figure 4A illustrates the ratio of pErk1/2 protein levels, normalized to total MAP kinase, in the mPFC across the two hemispheres. One-way ANOVA revealed a significant difference across groups (F(2,19) = 6.04; p < 0.01). For rats given either dose of RU 28362 into the left BLA, the ratio of pErk1/2 protein levels in the mPFC between the ipsilateral and contralateral side was significantly greater than that in rats administered vehicle (both doses, p < 0.01). In contrast, in rats that were not trained on the inhibitory avoidance task, pErk1/2 levels in the mPFC did not increase after infusions of RU 28362 into the BLA (F(2,12) = 0.18; p = 0.84). Figure 4B shows a representative example of an immunoblot illustrating pErk1/2 and total MAP kinase levels in the ipsilateral and contralateral mPFC of the different experimental groups. To qualitatively confirm the Western blot data, we determined immunoreactivity levels of pErk1/2 in the mPFC 15 min after a unilateral infusion of RU 28362 (3 ng) or vehicle into the left BLA. As is shown in Figure 4C, RU 28362 treatment in the BLA increased the density of pErk1/2-positive neurons in both the prelimbic and infralimbic regions of the ipsilateral mPFC compared with rats given a vehicle infusion, although pErk1/2-immunonegative neurons were also present in this group. The increased density of pErk1/2 cells was predominantly found in layers 2 and 3, in cells with a long apical dendrite. These cells most likely represent pyramidal cells.

A MEK inhibitor infused into the mPFC blocks retention enhancement induced by postraining infusion of a GR agonist into the BLA

To determine whether this increased pErk1/2 activity in the mPFC is involved in mediating the memory-enhancing effect of GR agonist infusions into the BLA, we examined whether a MEK inhibitor infused into the mPFC blocked this retention enhancement. Two-way ANOVA for entrance latencies on the training
trial, before footshock and drug treatment, did not show significant differences between groups (p > 0.13 for all comparisons) (data not shown). Figure 5 shows 48 h inhibitory avoidance retention latencies of rats given immediate posttraining infusions of the MEK inhibitor PD98059 (50 ng) or vehicle into the left mPFC together with the GR agonist RU 28362 (1 or 3 ng) or vehicle into the ipsilateral BLA. Two-way ANOVA for retention latencies revealed a significant RU 28362 effect (F(2,63) = 3.75; p < 0.05), a significant PD98059 effect (F(1,63) = 8.37; p < 0.01), as well as a significant interaction between both factors (F(2,63) = 4.67; p < 0.05). Posttraining infusion of the higher dose of RU 28362 (3 ng) into the BLA enhanced retention of rats given vehicle into the mPFC, compared with the retention of corresponding vehicle-treated rats (p < 0.01). Infusion of PD98059 into the ipsilateral mPFC did not impair retention latencies when administered alone (p = 0.95) but blocked the retention-enhancing effects of RU 28362 administered into the BLA. Furthermore, retention latencies of RU 28362-treated rats given PD98059 into the mPFC were significantly shorter than retention latencies of RU 28362-treated rats given vehicle into the BLA (3 ng, p < 0.01).

GR agonist infusions into the mPFC or BLA enhance memory for similar components of inhibitory avoidance training

If, as suggested by the findings described above, the mPFC and BLA function as a circuit in enhancing GR agonist effects on memory consolidation, then it may be expected that the BLA and mPFC enhance memory of the same components of information acquired during inhibitory avoidance training. In inhibitory avoidance, rats learn both that they received a footshock as well as where they received the footshock. However, with traditional one-trial inhibitory avoidance training, it is not possible to determine whether the GR agonist infusions into the BLA or mPFC specifically enhanced memory of the context exposure, the footshock experience, or of both components of training. Recently, a modified, two-phase inhibitory avoidance procedure was developed to separate the learning about the context from the learning about the footshock. On the first day, animals freely explore the inhibitory avoidance apparatus to learn about the context and 24 h later are very briefly placed back into the shock compartment to receive footshock (Malin and McGaugh, 2006). In the present experiment, rats were trained on the two-phase inhibitory avoidance procedure and given bilateral infusions of the GR agonist RU 28362 into either the BLA (1 or 3 ng in 0.2 µl) or mPFC (3 or 10 ng in 0.5 µl) after the context training or footshock training. Figure 6A shows 48 h retention latencies of animals given GR agonist infusions into the BLA immediately after context or shock training of inhibitory avoidance. One-way ANOVAs for retention latencies revealed significant group effects of rats given intra-BLA infusions of RU 28362 immediately after either context (F(2,32)= 6.55; p < 0.005) or shock training (F(2,35) = 5.52; p < 0.01). Retention latencies of rats given intra-BLA infusions of the 1 or 3 ng dose of RU 28362 immediately after either context or shock training were significantly longer than those of their respective

![Image](https://example.com/image1.png)

**Figure 3.** A MEK inhibitor infused into the BLA blocks inhibitory avoidance retention enhancement induced by posttraining GR agonist infusions into the mPFC. A, Step-through latencies (mean ± SEM) in seconds on the 48 h inhibitory avoidance retention test of rats given immediate posttraining infusions of the GR agonist RU 28362 (3 or 10 ng in 0.5 µl) into the left mPFC either alone or together with the MEK inhibitor PD98059 (20 ng in 0.2 µl) into the ipsilateral BLA. **p < 0.01 compared with the corresponding vehicle group; **p < 0.01 compared with the corresponding saline–RU 28362 group (n = 10–13 per group). B, Injection needle tips in the left mPFC and BLA of 30 randomly selected rats included in the experiment.

![Image](https://example.com/image2.png)

**Figure 4.** Infusions of the GR agonist RU 28362 (1 or 3 ng in 0.2 µl) into the BLA after inhibitory avoidance training increase pErk1/2 levels in the mPFC. A, Mean ratio (+ SEM) of pErk1/2 in the mPFC ipsilateral to BLA infusions versus pErk1/2 measured in the contralateral mPFC. Error bars represent SEM. B, Density of pErk1/2 bands was normalized to density of total MAP kinase bands on the same blot. The left band is ipsilateral (i) to intra-BLA infusion, and right is contralateral (c). C, Immunohistochemical demonstration of location of pErk1/2 within the mPFC. Positive cells were present in neurons in both the prelimbic and infralimbic regions of the ipsilateral mPFC, particularly in pyramidal cells of layers 2 and 3. Note pErk1/2 immunoreactivity in apical dendrites in this area.
GR agonist after either context (significant differences in retention latencies of animals given the training of inhibitory avoidance are shown in Figure 6). Posttraining infusions of RU 28362 or vehicle immediately after context or shock similar to the effects of BLA infusions, one-way ANOVAs revealed either alone or together with the MEK inhibitor PD98059 (50 ng in 0.5 µl) into the left BLA either exclusively or together with the MEK inhibitor PD98059 (50 ng in 0.5 µl) into the ipsilateral mPFC. *p < 0.01 compared with the corresponding vehicle group; **p < 0.01 compared with the corresponding vehicle–RU 28362 group (n = 10–13 per group).

Figure 5. A MEK inhibitor infused into the mPFC blocks inhibitory avoidance retention enhancement induced by posttraining GR agonist infusions into the BLA. Step-through latencies (mean ± SEM) in seconds on the 48 h inhibitory avoidance retention test of rats given immediate posttraining infusions of the GR agonist RU 28362 (1 or 3 ng in 0.2 µl) into the left BLA either alone or together with the MEK inhibitor PD98059 (50 ng in 0.5 µl) into the ipsilateral mPFC. *p < 0.01 compared with the corresponding vehicle group; **p < 0.01 compared with the corresponding vehicle–RU 28362 group (n = 10–13 per group).

### Discussion

These findings provide evidence that glucocorticoid effects on the consolidation of memory for inhibitory avoidance training depend on functional interactions between the BLA and mPFC. The memory-enhancing effect of an immediate posttraining infusion of the GR agonist RU 28362 administered into the mPFC depends on an increased phosphorylation of Erk1/2 in the BLA, and, similarly, the memory enhancement induced by intra-BLA administration of RU 28362 requires elevated pErk1/2 levels in the mPFC. Moreover, the finding that the GR agonist infused into either the BLA or the mPFC enhances the consolidation of memory of both the contextual and aversively motivated aspects of information acquired during inhibitory avoidance training strongly suggests that these two brain regions function as a bidirectional circuit in emotional regulation of memory consolidation.

Considerable evidence from electrophysiological studies indicates that the mPFC and BLA interact (Timms, 1977; Pérez-Jaranay and Vives, 1991; Rosenkranz and Grace, 2002; Maroun and Richter-Levin, 2003; Likhtik et al., 2005) and that mPFC–BLA interactions regulate performance on affectively motivated tasks (Schoenbaum et al., 1998; Bechara et al., 1999). For example, several studies implicate mPFC–BLA interactions in controlling the expression and extinction of conditioned fear (Garcia et al., 1999; Milad and Quirk, 2002). Moreover, we previously reported that lesions of the BLA block working memory impairment induced by intra-mPFC infusions of a GR agonist (Roozendaal et al., 2004). The present experiments investigated whether the mPFC and BLA interact in regulating the consolidation of memory of emotionally arousing training experiences. The first experiment determined that a lesion of the BLA made ipsilaterally to the mPFC infusion site blocked the GR agonist-induced memory enhancement, indicating that an intact and functional BLA is required for mediating the modulatory influences of intra-mPFC glucocorticoid administration on memory consolidation. As a contralateral BLA lesion did not block the GR agonist-induced memory enhancement, evidence indicates that the interaction is mediated directly through neural pathways connecting these two brain regions (Krettek and Price, 1977; Russchen, 1982) rather than by an effect of GR manipulation on hypothalamic–pituitary–adrenocortical axis activity. These findings are very similar to those of previous studies indicating that a disruption of BLA activity blocks memory enhancement induced by the administration of a glucocorticoid or other memory-enhancing compound into the hippocampus, dorsal striatum, entorhinal cortex, insular cortex, or anterior cingulate cortex (Roozendaal and McGaugh, 1997a; Roesler et al., 2002; Miranda and McGaugh, 2004; Malin et al., 2007) and further support the view that the BLA regulates memory consolidation via interactions with many brain regions (McGaugh, 2002).

Whereas previous findings suggest that the BLA regulates neuroplasticity and memory consolidation primarily through different projections from the BLA to these other brain regions (McGaugh, 2002), the present results indicate that interactions between the BLA and mPFC in modulating memory consolidation are bidirectional and, thus, that BLA activity does not simply regulate information storage processes in the mPFC. Our finding that the GR agonist infused unilaterally into the mPFC immediately after inhibitory avoidance training elevated pErk1/2 levels in the ipsilateral BLA shows that a manipulation of GR activity in the mPFC modulates BLA activity. The observation that the GR
agonist also increased pErk1/2 levels in the central part of the lateral division of the central amygdala, intercalated mass, and to a lesser extent the medial amygdala is consistent with evidence that the mPFC has projection neurons to these other regions (Cassell and Wright, 1986). We measured pErk1/2 levels to assess BLA activity because Erk is a rapidly activated protein that has been implicated in neuroplasticity and memory consolidation (Atkins et al., 1998; Schafe et al., 2000). Moreover, and most importantly, as the specific MEK inhibitor PD98059 infused selectively into the BLA blocked this memory enhancement, these findings suggest that this increased phosphorylation of Erk1/2 in the BLA is essential in mediating the memory-modulatory effect of intra-mPFC GR agonist administration. As some evidence suggests that the medial amygdala, but not the central amygdala, is also involved in regulating stress hormone effects on memory consolidation (Roozendaal and McGaugh, 1996), it is possible that mPFC influences on pErk1/2 activity within the medial amygdala normally contribute to the enhanced retention initiated by GR agonist infusion into the mPFC. Highly comparable with the effects of GR agonist infusions into the mPFC, RU 28362 administration into the BLA after inhibitory avoidance training induced a rapid increase in pErk1/2 levels in both the prelimbic and infralimbic regions of the mPFC. Furthermore, an immediate posttraining infusion of a MEK inhibitor into the mPFC blocked the memory enhancement induced by intra-BLA administration of the GR agonist. Thus, the findings indicate that a GR agonist infusion into the mPFC influences BLA activity, whereas a GR agonist infusion into the BLA alters mPFC activity. Interference with this process at either site prevents the enhancing effect of glucocorticoid administration on memory consolidation, likely by disturbing the processing of information storage occurring in distal brain regions (McGaugh, 2002; Roozendaal, 2002). To date, it is not known whether glucocorticoid modulation of memories in these distal brain regions also depends on increased pErk1/2 levels in the mPFC and/or BLA.

Interestingly, several findings indicate that glucocorticoid effects on memory consolidation depend on pErk1/2-MAP kinase activation. For example, Revest et al. (2005) reported that stress or corticosterone induced a slow-onset (after 2 h) increase in the expression and enzymatic activity of the MAP kinase pathway in the hippocampus. Blockade of this effect with intrahippocampal infusions of a MEK inhibitor prevented glucocorticoid effects on fear memory consolidation. Our data appear to differ in two important ways: First, our findings clearly demonstrate that GR agonist administration into either the mPFC or BLA induces pErk1/2 activation in the other brain site. Second, our data indicate elevated pErk1/2 levels in the mPFC or BLA within 15 min after GR agonist administration. Such a time frame strongly suggests the involvement of a nongenomic glucocorticoid action, possibly through an activation of membrane-associated receptors (Dallman, 2005; Johnson et al., 2005). Such findings are consistent with evidence of rapid interactions of glucocorticoids or GR agonists with arousal-induced noradrenergic and endocannabinoid mechanisms in influencing neuroplasticity and memory consolidation (Quirarte et al., 1997; Roozendaal et al., 2006; Pu et al., 2007; Campolongo et al., 2009). Also, the findings that the GR agonist did not alter pErk1/2 levels when infused into either the mPFC or BLA of nontrained control animals support the view that glucocorticoids affect BLA–mPFC circuitry and enhance memory consolidation only under conditions of emotional arousal.

Additional support for a necessary interaction between the BLA and mPFC in regulating glucocorticoid effects on memory consolidation in efferent brain regions was provided by our finding that both brain regions played a role in GR agonist effects on the consolidation of memory of contextual and aversively motivated aspects of inhibitory avoidance training. As noted above, BLA activation is known to enhance the consolidation of memory of many different training experiences via interactions with different brain regions (McGaugh, 2002). The present demonstration that the GR agonist administered into the mPFC, like infusions into the BLA, enhanced retention when administered after either the context training or footshock experience indicate that both brain regions share a functional commonality and strongly support the view that both brain regions cooperate in regulating memory consolidation. In contrast, previous experiments investigating the effect of drug administration into the hippocampus, anterior cingulate cortex, or dorsal striatum after training on the two-phase inhibitory avoidance task indicated that those brain regions are dedicated to the selective modulation of memory of specific components of the training experience (Malin and McGaugh, 2006; Medina et al., 2007; Roozendaal et al., 2008). These findings not only substantiate the unique roles of the BLA and mPFC, and their interaction, in emotional regulation of memory consolidation of many different types of training experiences (Tronel and Sara, 2003; Xiang and Brown, 2004; Touzani et al., 2007; McDonald et al., 2008), but also strongly suggest that drug infusions into these other brain regions do not simply enhance memory consolidation by activating the BLA and mPFC. Rather, these findings are consistent with our view that the BLA–mPFC circuit regulates memory consolidation in these other, distal brain regions. Several studies indicate that such interactions between the mPFC and BLA may be essential for an adaptive regulation of affect and memory (Amat et al., 2005) and to exert a cognitive and emotional control to downregulate limbic circuitry (Burgos-Robles et al., 2007; Mueller et al., 2008).

In summary, we demonstrate a crucial role for bidirectional interactions between the BLA and mPFC in regulating glucocorticoid effects on memory consolidation. Abnormalities in the BLA and mPFC are consistently noted in affective disorders such as post-traumatic stress disorder and major depressive illness (Bremner et al., 1999; Johnstone et al., 2007). The identification of the nature and functional dynamics of this BLA–mPFC circuit that modulate emotional arousal effects on memory consolidation may lead to an improved understanding of how this system may be involved in the aberrant cognitive and emotional responses observed in affective disorders.

### Table 1. Effect of RU 28362 after context or shock exposure alone

<table>
<thead>
<tr>
<th></th>
<th>Context exposure alone</th>
<th>Footshock exposure alone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle RU 28362</td>
<td>Vehicle RU 28362</td>
</tr>
<tr>
<td>BLA</td>
<td>10.1 ± 3.0 (7)</td>
<td>8.9 ± 2.9 (7)</td>
</tr>
<tr>
<td>p</td>
<td>0.38</td>
<td>0.46</td>
</tr>
<tr>
<td>mPFC</td>
<td>13.7 ± 1.7 (7)</td>
<td>13.2 ± 6.1 (5)</td>
</tr>
<tr>
<td>p</td>
<td>0.97</td>
<td>0.92</td>
</tr>
</tbody>
</table>

Shown are retention latencies (mean ± SEM) in seconds. The numbers of animals per group are indicated in parentheses. The dose of RU 28362 administered into the BLA was 3 ng in 0.2 μl and that into the mPFC was 10 ng in 0.5 μl.
References


